[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-stage-iii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-stage-iii":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,69,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100617162","phase-2-ql1706-sox-vs-sox-alone-as-neoadjuvant-therapy-for-resectable-diffuse-type-gastric-cancer-100617162",false,"NCT07315035","QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","A Randomized, Controlled, Phase-II Trial of Neoadjuvant QL1706 (Iparomlimab \u002FTuvonralimab) Combined With SOX Versus SOX Alone Followed by Curative Gastrectomy in Patients With Locally Advanced Diffuse-Type Gastric Adenocarcinoma","Inclusion Criteria:\n\nHistologically confirmed diffuse-type gastric adenocarcinoma (Lauren classification) with signet-ring cells ≥ 50 % of tumor volume HER2-negative by IHC or ISH per ASCO\u002FCAP guidelines Clinical stage cT3-4aNxM0 (AJCC 8th ed.) on baseline EUS + contrast-enhanced CT\u002FMRI; disease judged resectable by multidisciplinary team No prior gastric surgery, chemotherapy, radiotherapy, or immunotherapy for cancer Age 18-75 years; ECOG performance status 0-1 Adequate organ function (ANC ≥ 1.5 × 10⁹\u002FL, platelet ≥ 100 × 10⁹\u002FL, Hb ≥ 9 g\u002FdL, ALT\u002FAST ≤ 2.5 × ULN, TBIL ≤ 1.5 × ULN, creatinine ≤ 1.5 × ULN and calculated CrCl ≥ 60 mL\u002Fmin, INR\u002FPT ≤ 1.5 × ULN) within 14 days before randomization Left-ventricular ejection fraction ≥ 50 % by echocardiography; no clinically significant ECG abnormalities Negative serum β-hCG pregnancy test ≤ 7 days of first dose for women of child-bearing potential; agreement to use effective contraception through 6 months post-surgery Life expectancy ≥ 6 months Signed informed consent; able to comply with study procedures and follow-up\n\nExclusion Criteria:\n\nMixed or intestinal Lauren histology; mucinous or hepatoid variants Active gastrointestinal bleeding or endoscopic evidence of major vessel invasion Other malignancy within 5 years (except curatively treated basal-cell carcinoma, cervical carcinoma in situ, or superficial bladder cancer) Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4, or other T-cell co-stimulatory\u002Fantagonist agents Autoimmune disease requiring systemic immunosuppression within 2 years (e.g., prednisone \\> 10 mg\u002Fday equivalent) Receipt of live vaccine ≤ 30 days before first dose Known HIV-positive, active hepatitis B (HBsAg+ and HBV-DNA \\> 200 IU\u002FmL), or hepatitis C infection (HCV RNA positive) Active tuberculosis or history of incompletely treated TB Severe cardiovascular disease: NYHA class ≥ II heart failure, unstable angina, myocardial infarction ≤ 6 months, uncontrolled arrhythmia, or uncontrolled hypertension (systolic \\> 160 mmHg or diastolic \\> 100 mmHg) Peripheral neuropathy ≥ grade 2 per NCI-CTCAE v5.0 Pulmonary disease requiring systemic steroids (e.g., ≥ grade 2 pneumonitis) or oxygen therapy Active infection requiring systemic antibiotics, antivirals, or antifungals ≤ 7 days before first dose Known hypersensitivity to oxaliplatin, fluoropyrimidines, or Chinese hamster ovary cell-derived products Pregnancy or lactation Concurrent participation in another interventional clinical trial Any condition that, in the investigator's opinion, would compromise safe completion of protocol therapy or accurate assessment of outcomes","ALL","18 Years","75 Years",{"count":20,"type":21},74,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this randomized, open-label, phase II clinical trial is to determine whether adding the PD-1\u002FCTLA-4 bispecific antibody QL1706 to standard SOX chemotherapy increases the pathological complete response rate in adults aged 18-75 years with resectable, locally advanced, diffuse-type, HER2-negative gastric adenocarcinoma (cT3-4aNxM0). Participants will be randomly assigned (1:1) to receive 3-4 neoadjuvant cycles of QL1706 plus SOX or SOX alone every 3 weeks, followed by curative-intent gastrectomy with D2 lymphadenectomy, and will be monitored post-operatively every 3 months for 2 years and every 6 months thereafter for recurrence, survival, and safety.",[27],"Gastric Cancer Stage III",[29,30],"QL1706","Diffused-type Gastric Cancer","NOT_YET_RECRUITING","2025-12-18",{"date":34,"type":35},"2026-01-02","ACTUAL",{"date":37,"type":21},"2026-01-01",{"date":39,"type":21},"2030-12-31",{"name":41,"class":42},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100596826","phase-2-omega-3-supplementation-and-immunotherapy-in-gastric-cancer-a-phase-ii-trial-100596826","NCT07050524","Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial","Evaluating the Effect of Omega-3 Fatty Acids Supplementation on the Efficacy of Neoadjuvant Immunotherapy in Patients With Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicenter, Randomized, Controlled Phase II Clinical Trial","Inclusion Criteria:\n\n1. Age: Participants must be aged 18 years or older.\n2. Diagnosis: Confirmed diagnosis of locally advanced gastric or gastroesophageal junction adenocarcinoma, classified as clinical stage II or III according to the American Joint Committee on Cancer (AJCC) staging system.\n3. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, indicating that patients are fully active or restricted in physically strenuous activity but are capable of self-care.\n4. Histological Verification: Tissue confirmation of diagnosis must be obtained via biopsy, with adequate archival tumor tissue available for biomarker analysis if required.\n5. Organ Function: Adequate organ function as evidenced by laboratory tests:\n\n   Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm³ Platelet count ≥ 100,000\u002Fmm³ Hemoglobin ≥ 9 g\u002FdL Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) Total bilirubin ≤ 1.5 times the ULN (unless due to Gilbert's syndrome) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the ULN (≤ 5 times the ULN if liver metastases are present)\n6. Informed Consent: Ability and willingness to provide written informed consent prior to any study-related procedures.\n\nExclusion Criteria:\n\n1. Previous Therapy: Prior treatment with chemotherapy, radiation therapy, or immunotherapy for the current cancer diagnosis.\n2. Concurrent Malignancies: Presence of another active malignancy within the past 5 years (except for non-melanoma skin cancer or cervical carcinoma in situ).\n3. Active Infection: Presence of any uncontrolled infection requiring systemic therapy or serious co-morbid conditions that would compromise program compliance or interfere with study results.\n4. Allergies: Known hypersensitivity or contraindications to Omega-3 fatty acid supplementation or components of the immunotherapy regimen.\n5. Pregnancy\u002FBreastfeeding: Women who are pregnant or breastfeeding; fertile men and women not employing effective contraception during the study period.\n\nPsychiatric Condition: Any psychiatric condition or substance abuse that would interfere with compliance or affect the participant's safety.","80 Years",{"count":53,"type":21},80,[24],"The goal of this clinical trial is to learn if Omega-3 fatty acids supplementation can enhance the efficacy of neoadjuvant immunotherapy in patients with locally advanced gastric and gastroesophageal junction adenocarcinoma. The main questions it aims to answer are: does Omega-3 supplementation improve the pathologic complete response (pCR) rate compared to standard neoadjuvant immunotherapy alone, and is there an increase in the major pathological response (MPR) rate with Omega-3 supplementation? Researchers will compare the group receiving Omega-3 supplementation with the control group receiving standard neoadjuvant immunotherapy to see if Omega-3 supplementation leads to better treatment outcomes. Participants will receive Omega-3 fatty acids supplements in conjunction with their prescribed neoadjuvant immunotherapy, undergo regular assessments of their pathologic response to treatment, and provide information on their nutritional status and quality of life throughout the study.",[27],[58,59,60],"omega-3","Neoadjuvant Immunotherapy","Gastric Cancer","2025-06-26",{"date":63,"type":35},"2025-07-03",{"date":65,"type":21},"2025-09-01",{"date":67,"type":21},"2027-09-30",{"name":41,"class":42},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100574151","phase-3-investigation-of-impact-of-indocyanine-green-on-volume-of-lymphadenectomy-in-resectable-gastric-cancer-100574151","NCT06755554","Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer","Investigation of Effect of Indocyanine Green on Volume of Lymph Node Dissection in Surgical Treatment of Gastric Cancer","ICGastr","Inclusion Criteria:\n\n* Tumor spread: cT2-4a cN0-3,\n* cM0;\n* Age: 18 - 80;\n* Gender: men and women;\n* ECOG: 0 - 1;\n* Histologic type of tumor: Adenocarcinoma of any subtype;\n* Degree of differentiation: G1 - G4;\n* Tumor localization: cardiac region, stomach floor, stomach body, antrum, pylorus, and pyloric region of the stomach;\n* Tumor spread: absence of tumor invasion into adjacent structures;\n* No history of cancer in the last 5 years;\n* No previous chemotherapy, surgery or radiation treatment for another cancer (except for neoadjuvant chemotherapy for gastric cancer);\n* Absence of severe comorbidity restricting laparoscopic approach.\n\nExclusion Criteria:\n\n* M1 (distant metastases);\n* ECOG 2 - 4;\n* Age over 80 and under 18;\n* Presence of severe comorbidities, ASA\\> 3;\n* Patient refusal to participate in the study.",{"count":78,"type":21},105,[80],"PHASE3","The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of lymph nodes removed. Secondary study points are the average number of ICG-positive lymph nodes; the average number of metastatic ICG-positive lymph nodes; the number of postoperative complications and complications associated with the administration of ICG.\n\nPatients who meet the inclusion criteria for this study will be enrolled in the study after reviewing and signing an informed consent form.\n\nAll patients will be included in one group and will receive surgical treatment in the amount of total or subtotal gastrectomy with lymphadenectomy D1, D1+, D2 or D2+.\n\nICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.\n\nAssessment of the number of fluorescent lymph nodes will be performed intraoperatively with their subsequent removal and mapping. The incidence of postoperative complications will be assessed by Clavien-Dindo.",[83,27,60,84],"Gastric Cancer Stage II","Gastrectomy for Gastric Cancer",[86,87,88],"indocyanine green","gastric cancer","gastrectomy","RECRUITING","2025-03-25",{"date":92,"type":35},"2025-03-30",{"date":94,"type":35},"2025-01-01",{"date":96,"type":21},"2026-02-01",{"name":98,"class":42},"Ukrainian Society of Clinical Oncology",2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":43},"100519396","a-multicenter-rct-study-of-the-clinical-efficacy-of-robotic-and-laparoscopic-gastrectomy-in-neoadjuvant-gastric-cancer-100519396","NCT06042998","A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer","A Prospective, Multicenter, Randomized, Controlled Study of the Clinical Efficacy of Robotic and Laparoscopic Radical Gastrectomy in Neoadjuvant Gastric Cancer Patients","CLASS14","Inclusion Criteria:\n\n1. 18 years old ≤ 75 years old male or female;\n2. The primary gastric lesion was diagnosed as gastric adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma) by endoscopic biopsy histopathology;\n3. Before neoadjuvant treatment, the preoperative clinical staging was confirmed to be II and III (cT2N+M0 or cT3-4a\u002FN+M0) through gastroscopy\u002Fultrasound gastroscopy, enhanced CT\u002FMR, or diagnostic laparoscopic exploration (based on AJCC-8th TNM tumor staging);\n4. 2-4 cycles of neoadjuvant therapy (chemotherapy+\u002F- targeted\u002Fimmunotherapy, simple chemotherapy);\n5. After new adjuvant treatment, radical Gastrectomy is feasible after MDT discussion;\n6. Preoperative ECOG physical condition score of 0\u002F1 or Karst score ≥ 70%;\n7. Preoperative ASA score I-III;\n8. The expected survival period exceeds 6 months;\n9. Willing and able to comply with the research protocol;\n10. Sign a written informed consent form before enrollment and be fully aware of the right to withdraw from this study at any time.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Suffering from serious mental illness;\n3. History of upper abdominal surgery (excluding history of laparoscopic cholecystectomy);\n4. History of gastric surgery (excluding ESD\u002FEMR for gastric cancer);\n5. Moderate to severe renal insufficiency;\n6. Organ transplant recipients receiving immunosuppressive therapy;\n7. Have a history of other malignant diseases within 5 years;\n8. Have a history of unstable angina or myocardial infarction within 6 months;\n9. Have a history of cerebral infarction or cerebral hemorrhage within 6 months;\n10. Have a history of continuous systemic corticosteroid therapy within one month;\n11. Simultaneous surgical treatment of other diseases is required (excluding laparoscopic cholecystectomy);\n12. Gastric cancer comorbidities (bleeding, perforation, obstruction) requiring emergency surgery;\n13. Lung function test FEV1\\\u003C50% of expected value;\n14. The patient has participated or is currently participating in other clinical studies (within 6 months).",{"count":109,"type":21},588,[111],"NA","To evaluate the clinical efficacy of robot radical Gastrectomy and laparoscopic radical Gastrectomy, patients with gastric adenocarcinoma (cT2N+M0 or cT3-4a\u002FN+M0, phase II and III) undergoing neoadjuvant treatment were selected as subjects.",[83,27],[115,87,116,117,118,119],"Neoadjuvant therapy","robot radical gastrectomy","laparoscopic Gastrectomy","short-term clinical outcome","prognosis","2023-09-12",{"date":122,"type":35},"2023-09-21",{"date":124,"type":35},"2023-07-07",{"date":126,"type":21},"2027-12-30",{"name":128,"class":42},"The Affiliated Hospital of Qingdao University"]